MARKET

GILD

GILD

Gilead Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

72.51
-2.25
-3.01%
Pre Market: 73.85 +1.34 +1.85% 06:42 04/02 EDT
OPEN
74.32
PREV CLOSE
74.76
HIGH
74.39
LOW
72.00
VOLUME
12.18M
TURNOVER
--
52 WEEK HIGH
85.97
52 WEEK LOW
60.89
MARKET CAP
91.29B
P/E (TTM)
17.23
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 29 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GILD stock price target is 74.50 with a high estimate of 90.00 and a low estimate of 53.00.

EPS

GILD News

More
  • Jim Cramer: Investors can 'learn a lot' from first-quarter winners and losers
  • CNBC.com · 10h ago
  • How to Trade Gilead Sciences as It Works on a Coronavirus Treatment
  • TheStreet.com · 15h ago
  • Covid Report: Testing News Sends One Biotech Flying As Another Dives
  • Investor's Business Daily · 16h ago
  • Tiny Bay Area company aims to win coronavirus vaccine race with a tablet
  • American City Business Journals · 20h ago

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About GILD

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
More

Webull offers kinds of Gilead Sciences, Inc. stock information, including NASDAQ:GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions.